News
FDA Suspends U.S. License of Chikungunya Vaccine
By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports of serious side effects in older adults similar to the symptoms of chikungunya virus.
FDA Suspends Valneva Vaccine’s License Following New Reports of Adverse Events
Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a pause on dosing of Ixchiq, but the agency’s new safety alert is based on an assessment that found the vaccine appears to be causing chikungunya-like illness in recipients.
The MIT professor of management, who already sits on the CDC's revamped immunization advisory committee, is a known skeptic ...
A rash typically appears a few days after the cold-like symptoms, starting on the face and behind the ears before spreading ...
The U.S. Centers for Disease Control and Prevention has chosen Retsef Levi, a member of its key vaccine panel, to lead its ...
The White House has denied reports that the government could soon ban COVID-19 vaccines, noting that in the absence of an ...
The Trump administration will move to pull the COVID vaccine off the U.S. market “within months,” one of Robert F. Kennedy Jr ...
The American Academy of Pediatrics and CDC have shared different recommendations for children getting COVID-19 vaccines. Here ...
The immunization appears to be most effective in preventing related hospitalizations if an older patient receives their RSV ...
Those with private health insurance expected to have an easier time getting vaccines than those on Medi-Cal if CDC changes ...
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS ...
An international team of scientists has found that a promising African swine fever (ASF) vaccine can protect pigs against ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback